The Committee to Evaluate Drugs (CED) is an independent expert advisory group that makes recommendations to the Executive Officer. Formerly known as the Drug Quality and Therapeutics Committee, the CED is the Ministry's expert advisory committee on drug-related issues. The CED's key mandate is the review of manufacturers' drug submissions for Formulary listing consideration.

The CED evaluates the clinical value of drug products, interchangeability of generic drug products and cost-effectiveness of drugs and makes recommendations to the Executive Officer regarding coverage of these products through Ontario Public Drug Programs and the New Drug Funding Program for cancer care. The CED also provides the Ministry with advice on a broad range of policy issues relating to the use of drugs.

Making the CED recommendations and Executive Officer decisions public provides a rational and balanced representation of the value of new drugs.

See also :

• The CED/Cancer Care Ontario (CCO) Subcommittee
• Recommendations from the Committee to Evaluate Drugs (CED) and Executive Officer Decisions